Cancer Family
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
CI-CAN-00000175Explore in graph →
Non-malignant81 active trials1 approved drugs18 evidence items
- NCIt
- C27291
Loading cancer entity…
Cancer Family
CI-CAN-00000175Explore in graph →
Clinical trials
253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03600649 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | unknown | Phase 1 | 50 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04735289 | Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma(Metabol-Sarc) | unknown | — | 810 | Istituto Ortopedico RizzoliOTHER | 1 | Aug 4, 2023 |
| clinicaltrials |
| NCT05266196 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | unknown | Phase 1 / Phase 2 | 10 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03359005 | Irinotecan and Temozolomide for Ewing Sarcoma | unknown | Phase 2 | 60 | Peking University People's HospitalOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02013336 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | unknown | Phase 1 | 30 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02856048 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer(PRESOV) | unknown | Phase 2 / Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02409576 | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas(NKEXPSARC) | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03416517 | Anlotinib and Irinotecan for Ewing Sarcoma | unknown | Phase 1 / Phase 2 | 47 | Peking University People's HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01807468 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | unknown | Phase 2 | 12 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT02509234 | Trabectedin and Irinotecan for Refractory Pediatric Sarcomas(TrIPReSarc) | unknown | — | 30 | Technical University of MunichOTHER | 0 | Jul 27, 2015 | clinicaltrials |
| NCT01780779 | Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults(FUBEO) | unknown | — | 25 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00541411 | Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma | unknown | N/A | 10 | King Faisal Specialist Hospital & Research CenterOTHER | 0 | Apr 17, 2012 | clinicaltrials |
| NCT00179816 | Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors | unknown | Phase 1 / Phase 2 | 12 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Oct 11, 2010 | clinicaltrials |
| NCT00180947 | Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse | unknown | Phase 2 | 210 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 8, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Nov 21, 2023source: clinicaltrials